Future Fields vs yhangry

Side-by-side comparison of AI visibility scores, market position, and capabilities

Future Fields leads in AI visibility (44 vs 41)

Future Fields

EmergingHealthcare

General

Precision fermentation biotech producing animal-free growth factors for cultivated meat and cell therapy; Drosophila expression system enabling lower-cost recombinant protein production.

AI VisibilityBeta
Overall Score
C44
Category Rank
#1036 of 1167
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
35
Perplexity
45
Gemini
40

About

Future Fields is a precision fermentation biotechnology company producing recombinant growth factors and proteins for the cultivated meat and cell therapy industries — using Drosophila (fruit fly) expression system to manufacture animal-free, scalable alternatives to animal serum-derived growth factors that are a major cost driver in cell-based biotech production. Founded in 2019 by Matthew Anderson-Baron and Jalene Anderson-Baron in Edmonton, Canada, Future Fields has raised approximately $11 million and targets the cultivated meat industry and cell therapy manufacturers who need cost-effective, animal-free growth factor supply.\n\nFuture Fields' EntoEngine platform uses genetically modified Drosophila to produce recombinant proteins (growth factors like FGF, EGF, IGF, TGF) at lower cost than mammalian cell expression systems — the Drosophila system is faster to scale, has lower infrastructure requirements, and produces proteins at commercially viable price points. For the cultivated meat industry, growth factors represent one of the largest cost components in cell culture media, and animal-free sources are preferred both for cost and for meeting "animal-free" product claims.\n\nIn 2025, Future Fields competes with Mycenax Biotech, Ajinomoto, and conventional growth factor suppliers for the cell culture media market. The cultivated meat industry has faced headwinds as commercialization timelines have extended and regulatory approvals have been slower than anticipated, but cell therapy (CAR-T, stem cell therapy, gene therapy) manufacturing represents a large adjacent market for Future Fields' growth factors. The 2025 strategy focuses on growing revenue from cell therapy manufacturers who need GMP-grade recombinant proteins, continuing to reduce production costs, and positioning as the commercial-scale alternative to FBS-derived growth factors.

Full profile

yhangry

EmergingHospitality

General

UK private chef marketplace with 900+ chefs and $6.7M annualized revenue; 45-65% word-of-mouth growth backed by YC and Goodwater Capital expanding to US in 2025.

AI VisibilityBeta
Overall Score
C41
Category Rank
#266 of 1167
AI Consensus
65%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
47
Gemini
51

About

yhangry is a London-based marketplace connecting customers with 900+ private chefs for in-home dining experiences — enabling individuals, couples, and groups to book a professional chef who shops for ingredients, cooks a multi-course meal in the customer's kitchen, and handles cleanup, for occasions ranging from date nights to dinner parties and corporate events. Founded in 2022 and backed by Y Combinator, Goodwater Capital, and prominent angels with $3.5 million raised, yhangry achieved $6.7 million in annualized revenue in 2024 with 5,300+ bookings and prepares for US expansion in 2025.

Full profile

AI Visibility Head-to-Head

44
Overall Score
41
#1036
Category Rank
#266
78
AI Consensus
65
stable
Trend
stable
35
ChatGPT
52
45
Perplexity
47
40
Gemini
51
40
Claude
51
39
Grok
38

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.